UFF
ANIK icon

USA Financial Formulas’s Anika Therapeutics ANIK Stock Holding History

USA Financial Formulas’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,456
Closed -$75K – 208
2019
Q4 		$75K Sell
1,456
-2,737
-65% -$159K 0.03% 176
2019
Q3 		$230K Buy
+4,193
New +$215K 0.09% 124
2016
Q3 		– Sell
-7,913
Closed -$425K – 229
2016
Q2 		$425K Buy
+7,913
New +$373K 0.12% 149

Other funds holding ANIK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

USA Financial Formulas's ANIK Position: Q1 2020 in Review

USA Financial Formulas sold out of Anika Therapeutics (ANIK) in Q1 2020, closing a stake of 1,456 shares — an estimated $75K sold.

USA Financial Formulas first reported a position in ANIK in Q2 2016 and held it in 3 quarters. The position peaked at $425K in Q2 2016. 163 funds tracked by Wall St. Rank hold ANIK as of Q1 2020.

  • USA Financial Formulas reported no remaining Anika Therapeutics position as of Q1 2020 after selling out during the quarter.
  • USA Financial Formulas sold 1,456 Anika Therapeutics shares in Q1 2020, an estimated $75K.
  • USA Financial Formulas first reported a position in Anika Therapeutics in Q2 2016 and held it in 3 quarters.
  • USA Financial Formulas's Anika Therapeutics position peaked at $425K in Q2 2016.
  • 163 funds tracked by Wall St. Rank held Anika Therapeutics as of Q1 2020.

Based on USA Financial Formulas's 13F filing for Q1 2020, filed 13 Apr 2020.